Vaccines are the biological preparation used for stimulating antibody production to activate immune system against diseases such as influenza, Hepatitis A, Hepatitis B, Human Papillomavirus, Polio, and Rabies. High prevalence of infectious disease and increasing governmental initiative for implementing nationalized vaccination programme are expected to drive growth of the vaccine market, whereas high developmental cost of vaccine is expected to hamper growth of the vaccine market. For instance, according to the Centers for Disease Control and Prevention (CDC), 2015, flu vaccinations prevented an around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden in the U.S.

Market Dynamics

The global disease control and prevention vaccine market is projected to witness significant growth over the forecast period, owing to rapid advancements in technology for development of novel vaccines such as recombinant and cell-based technologies, resulting in increasing production of the vaccines. For instance, in 2018, collaboration between Austrian biotech Themis Bioscience and Oslo-based Coalition for Epidemic Preparedness Innovations (CEIP). CEIP will fund US$ 37.5 million for vaccine development for five years. Moreover, governmental bodied supports the research and development program leading to the development of improved form of presently available vaccines. For instance, in 2015, a National Institute of Allergy and Infectious Disease scientists engineered a protein to maintain the specific shape of the viral spike, stimulating the immune system to produce powerful anti-HIV antibodies. However, manufacturing cost as well as large gap between demand and supply leading to hike in pricing is expected to hinder the growth of disease control and prevention vaccination market.

Key features of the study

• This report provides in-depth analysis of the disease control and prevention vaccine  market and its Type, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2017 – 2025, considering 2016 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global disease control and prevention vaccine market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
• Key companies covered as a part of this study include GlaxoSmithKline plc (GSK), Merck & Co. Inc., Sanofi, AstraZeneca PLC, Pfizer, Inc., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Astellas Pharma Inc., and Daiichi Sankyo
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion and marketing tactics.
• The global disease control and prevention vaccine market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for disease control and prevention vaccine market, research and consulting firms, new entrants and financial analysts.

Market Segmentation

• By Product Type (Revenue, USD Bn, 2021-2033)
  • Live-attenuated Vaccines
  • Inactivated Vaccines
  • Recombinant Vaccines
  • Toxoid Vaccines
• By Type (Revenue, USD Bn, 2021-2033)
  • Monovalent Vaccines
  • Multivalent Vaccines
• By Route of Administration (Revenue, USD Bn, 2021-2033)
  • Oral
  • Injectable
• By Age Group (Revenue, USD Bn, 2021-2033)
  • Pediatric Vaccines
  • Adult Vaccines
• By Indication (Revenue, USD Bn, 2021-2033)
  • Infectious Diseases
  • Cancer
  • Other Indications
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
•  Company Profiles
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Sanofi Pasteur
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Johnson & Johnson
  • Moderna, Inc.
  • BioNTech SE
  • Novavax, Inc.
  • Sinovac Biotech Ltd.
  • Serum Institute of India Pvt. Ltd.
  • Bharat Biotech International Ltd.
  • CSL Limited
  • Dynavax Technologies Corporation
  • Valneva SE Inovio Pharmaceuticals, Inc.
  • Vaxart, Inc.
  • Astellas Pharma Inc.
  • Daiichi Sankyo Company
  • Limited and Panacea Biotec Ltd.